Phlow Corporation is a U.S.-based public-benefit pharmaceutical manufacturer specializing in onshore continuous-flow production of medicines and APIs. The company was awarded a landmark $354 million HHS/ASPR/BARDA contract to manufacture essential medicines in shortage, strengthening America's pharmaceutical supply chain. Phlow has raised $37 million in Series C funding to expand U.S.-based CDMO operations. The company partners with Fresenius Kabi for the first-ever end-to-end U.S. manufacturing of Epinephrine Injection USP, with Antheia for advanced manufacturing technologies, and with USP for pharmaceutical continuous manufacturing. Phlow is driving sustainable cost competitiveness through advanced manufacturing technology including continuous flow chemistry and AI-enhanced analytics.
Continuous-flow API manufacturing, onshore U.S. pharmaceutical supply chain, essential medicines manufacturing, advanced manufacturing technologies, AI-enhanced analytical capabilities
1 site worldwide
No reviews available yet.
No documents available.